Progesterone and the risk of preterm birth among women with a short cervix.

@article{Fonseca2007ProgesteroneAT,
  title={Progesterone and the risk of preterm birth among women with a short cervix.},
  author={Eduardo Borges da Fonseca and Ebru Çelik and Mauro Parra and Mandeep Singh and Kypros H. Nicolaides},
  journal={The New England journal of medicine},
  year={2007},
  volume={357 5},
  pages={
          462-9
        }
}
BACKGROUND Previous randomized trials have shown that progesterone administration in women who previously delivered prematurely reduces the risk of recurrent premature delivery. Asymptomatic women found at midgestation to have a short cervix are at greatly increased risk for spontaneous early preterm delivery, and it is unknown whether progesterone reduces this risk in such women. METHODS Cervical length was measured by transvaginal ultrasonography at a median of 22 weeks of gestation (range… 

Figures and Tables from this paper

Vaginal Progesterone in Asymptomatic Women with Short Cervical Length on Ultrasound: is it Beneficial?

In a woman with short cervical length, vaginal progesterone significantly lowers the preterm birth rate and composite neonatal morbidity.

Treatment options and recommendations to reduce preterm births in women with short cervix.

Results of the recent PREGNANT trial, consistent with the earlier Fetal Medicine Foundation study, support the use of vaginal progesterone for prevention of preterm birth.

Prophylactic progesterone and preterm labor in low-risk twin pregnancies

Although vaginal progesterone reduces preterm birth and neonatal complications in singletons with a short cervix, its role in twin pregnancies with a normal cervical length is unclear and needs a larger study to prove its merit.

VAGINAL PROGESTERONE PESSARY FOR PRETERM LABOR PREVENTION IN WOMEN WITH A SHORT CERVIX EARLY IN THE SECOND TRIMESTER

  • E. Khazaali
  • Medicine
    Iraqi Journal of Medical Sciences
  • 2018
Vaginal progesterone pessaries in women with a cervical length less than 30 mm early in the second trimester are found to be effective in reducing the rate of preterm birth and some of the prematurity related morbidity events.

Vaginal progesterone in risk reduction of preterm birth in women with short cervix

A standard prenatal care does not include methods to predict or prevent spontaneous preterm birth, which accounts for high neonatal morbidity, mortality and healthcare expenses to the society.

Cerclage versus vaginal progesterone in low-risk pregnant women with a short cervix

  • Olivet MartinezH. Moran Angela S. Martin
  • Medicine
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • 2022
No difference was found between vaginal progesterone and cerclage in the average latency period or risk of preterm birth among women with an incidental short cervix of <15 mm and no history of pre term birth, despite the significantly shorter initial cervical length in the cerclages group.

Preventing preterm birth with progesterone: costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study

This study will provide evidence for the usefulness and cost-effectiveness of screening for short cervical length at the 18-22 weeks and subsequent progesterone treatment among low risk women.

Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety

Vaginal progesterone administration in asymptomatic twin pregnancies with sonographic short cervix at 20–24 weeks of gestation is effective and safe treatment for reducing the incidence of preterm labor with subsequent reduction in the neonatal morbidities and mortality associated with preterm birth.

The prevalence of short cervix between 20 and 24 weeks of gestation and vaginal progesterone for prolonging of gestation

  • Malipati MaerdanC. ShiXiao-xiao ZhangL. Fan
  • Medicine, Biology
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • 2017
Vaginal progesterone is efficacious for the prolonging of gestation in women with a cervical length of 10–20 mm in the mid-trimester for a singleton gestation and nulliparous women.

Preventing Preterm Birth with Progesterone in Women with a Short Cervical Length from a Low-Risk Population: A Multicenter Double-Blind Placebo-Controlled Randomized Trial.

In women with a short cervix, who are otherwise low risk, it could not show a significant benefit of progesterone in reducing adverse neonatal outcome and PTB.
...

References

SHOWING 1-10 OF 27 REFERENCES

The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network.

The risk of spontaneous preterm delivery is increased in women who are found to have a short cervix by vaginal ultrasonography during pregnancy.

Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study.

Prophylactic vaginal progesterone reduced the frequency of uterine contractions and the rate of preterm delivery in women at high risk for prematurity in a high-risk population.

Prenatal administration of progesterone for preventing preterm birth.

Intramuscular progesterone is associated with a reduction in the risk of preterm birth less than 37 weeks' gestation, and infant birthweight less than 2500 grams.

A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.

Treatment with 17 alpha-hydroxyprogesterone caproate did not reduce the rate of preterm birth in women with twin gestations.

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.

to the editor: After reading the article by Meis et al. (June 12 issue), 1 we strongly discourage practitioners from using 17 alpha-hydroxyprogesterone caproate in the care of women who have had

Neurologic and developmental disability at six years of age after extremely preterm birth.

Among extremely preterm children, cognitive and neurologic impairment is common at school age and a comparison with their classroom peers indicates a level of impairment that is greater than is recognized with the use of standardized norms.

Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration.

Low dose micronized progesterone administered vaginally is simple, easy and well tolerated, it could be recommended as the method of choice for luteal support, especially for high responder patients at risk for ovarian hyperstimulation syndrome.

Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation.

  • R. Brent
  • Medicine
    Birth defects research. Part A, Clinical and molecular teratology
  • 2005
It is obvious that clinically utilized progestational drugs do not cause nongenital malformations, and it took 22 years from the time a box warning was required by the FDA until the warnings were removed in 1999.